Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Buy” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $17.29.

A number of brokerages recently commented on REPL. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. Jefferies Financial Group lifted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th.

Replimune Group Stock Performance

Replimune Group stock opened at $12.55 on Friday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $858.67 million, a P/E ratio of -4.11 and a beta of 1.26. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a 50-day moving average of $12.19 and a 200-day moving average of $10.45.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Sell-side analysts expect that Replimune Group will post -2.91 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its stake in Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after buying an additional 217,308 shares in the last quarter. State Street Corp grew its holdings in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after acquiring an additional 238,747 shares in the last quarter. Finally, Arizona PSPRS Trust purchased a new position in Replimune Group in the 3rd quarter worth approximately $834,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.